Background: Tumor necrosis factor (TNF)-α can upregulate the expression of plasminogen activator inhibitor (PAI)-1, an inhibitor of fibrinolysis. Adiponectin (Adp) antagonizes TNF-α by negatively regulating its expression in various tissues. In the present study, the ability of Adp to suppress TNF-α-induced PAI-1 upregulation and the underlying mechanisms were evaluated. Methods: Human umbilical vein endothelial cells (HUVECs) were treated with TNF-α in the presence or absence of Adp, and PAI-1 mRNA and antigen expression, activated signaling pathways, and molecular mechanisms were analyzed by qRT-PCR and ELISA. Results: Adp decreased the TNF-α-induced upregulation of PAI-1 mRNA and protein expression and suppressed TNF-α-induced cAMP-PKA-AMPK inactivation. Adp also suppressed the TNF-α-induced NF-kB binding capability on the PAI-1 promoter. Moreover, these Adp-induced effects were further enhanced or prevented by treatment with the cAMP inhibitor Rp-cAMPs or activator forskolin, respectively. Conclusions: Our data suggest that Adp abrogates TNF-α-activated PAI-1 expression by activating cAMP-PKA-AMPK signaling to suppress NF-kB binding to the PAI-1 promoter in HUVECs. Given the antifibrotic effect of PAI-1 abrogation, Adp may be utilized as a novel agent in the treatment of fibrotic diseases.
Introduction
Atherosclerosis-associated cardiovascular disease is the leading cause of death in developed countries, and its incidence is increasing rapidly in developing countries. It has been predicted that atherosclerosis will be the primary cause of death worldwide by 2020 [1] . Atherosclerosis is a chronic, systemic disease and multiple factors are involved in its initiation and progression [2] , with a growing body of evidence pointing to inflammation and endothelial dysfunction as key factors [3] .Endothelial dysfunction could cause abnormalities of the fibrinolytic system, which plays a significant role in the development of atherosclerotic plaques [4] . Plasminogen activator inhibitor-1 (PAI-1) is the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), and hence is an inhibitor of fibrinolysis [5] .PAI-1 plays a pivotal role in cardiovascular diseases, including arteriosclerosis, since atheroscleroticlesions tend to show increasedPAI-1expression levels [6] . Therefore, studies are needed to determine the regulatory mechanism of PAI-1 expression in order to gain a better understanding of the development of atherosclerosis-associated cardiovascular disease.
Activation of vein endothelial cells by various inflammatory stimuli, including tumor necrosis factor-alpha (TNF-α), increases the adherence of monocytes, which is considered a crucial step in the development of vascular diseases. Adiponectin (Adp) is an important adipokine involved in the control of fat metabolism and insulin sensitivity, with direct anti-diabetic, anti-atherogenic, and anti-inflammatory activities. Adp can antagonize TNF-α by negatively regulating its expression in various tissues, such as the liver, as well as in macrophages, and by counteracting its effects. Indeed, low Adp levels are associated with vascular dysfunction, and Adp-based treatment is beneficial for atherosclerosis and endothelial cell dysfunction [7] . In human umbilical vein endothelial cells (HUVECs), TNF-α treatment could increase both PAI-1 mRNA expression and protein release [8, 9] . Therefore, we hypothesized that Adp might be a key factor involved in inhibiting TNF-α-induced PAI-1 expression.
Adp can stimulate AMP-activated protein kinase (AMPK) phosphorylation and activation in liver cells, thereby enhancing glucose utilization and fatty acid combustion [10] . In addition, Adp can inhibit endothelial nuclear factor-kappa B (NF-κB) activity stimulated by TNF-α via a cAMP-dependent pathway in human aortic endothelial cells [11] . Furthermore, we previously reported that Adp treatment could inhibit TNF-α-induced NF-kB P65 activity in HUVECs and increase the AMPK phosphorylation level [12] . Therefore, the aim of the present study was to examine whether Adp regulates TNF-α-induced PAI-1 expression via the cAMP-AMPK-NF-k-B signaling pathway.
To test this hypothesis, HUVECs were treated with TNF-α in the absence and presence of Adp, and the effects on PAI-1 mRNA and protein expression were evaluated by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and enzymelinked immunosorbent assay (ELISA), respectively. In addition, the binding capacity of NF-κB on the PAI-1 promoter was assessed under various treatments with chromatin immunoprecipitation (ChIP) assays using mutant promoter constructs. The role of the cAMP/protein kinase A (PKA) signaling pathway was evaluated using specific inhibitors to determine the underlying regulatory mechanism. These results are expected to provide new insights into the molecular pathological mechanisms contributing to the development and progression of atherosclerosis and suggest new treatment targets.
Materials and Methods

HUVEC isolation and culture
HUVECs were isolated from human umbilical cords collected from normal deliveries at the First Affiliated Hospital of Gannan Medical University. Signed consent was obtained from all donors, and the study was approved by the Institutional Review Board of the First Affiliated Hospital of Gannan Medical University. The vein in the cord was washed with pre-warmed phosphate-buffered saline (PBS) using a 50-ml syringe and then filled with Hanks' balanced salt solution (HBSS) containing 0.2% collagenase type II. After 15 min, HBSS was collected in a tube and centrifuged at 300 × g for 5 min. Isolated cells were plated in 100-mm-diameter culture dishes coated with 0.1% gelatin (Sigma Aldrich, St. Louis, MO, USA) and cultured in M199 medium containing 10% fetal bovine serum and 1% antibiotics. The cells were grown at 37°C in a humidified atmosphere with 5% CO 2 . The cells plated on the culture dish were regarded as passage 0, and those obtained from passages 3 to 4 were used in the experiments.
Cell treatments
To detect the effect of TNF-α on PAI-1 expression, HUVECs were treated with various concentrations of recombinant TNF-α protein (1, 10, 20, 50, or 100 ng/ml) for 12 h or with 10 ng/ml TNF-α for 1 , 3 , 6 , 12 , or 24 h. To detect the suppressive effect of Adp on TNF-α-induced effects, HUVECs were treated with 10 ng/ml TNF-α plus 0 (control), 10 µg/ml, 20 µg/ml, or 30 µg/ml Adp. To detect the role of the cAMP/PKA pathway in the regulation of Adp and TNF-α-induced effects, HUVECs were treated with 10 ng/ml TNF-α plus 30 µg/ ml Adp in the presence or absence of a cAMP/PKA pathway inhibitor (10 µM RP-cAMPs) or activator (10 µM forskolin).
RNA extraction, reverse transcription, and PCR
Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. cDNA was synthesized from RNA using M-MLV reverse transcriptase (Promega, Madison, WI, USA) in a 25-μl volume. Expression levels were quantitated by real-time PCR using the ABI PRISM 7500 sequence detection system with SYBR Green qPCR SuperMix (Invitrogen). The expression level of each mRNA was normalized to that of β-actin (endogenous control) and calculated using the 2 -ΔΔCt method. The primers were as follows: PAI-1-F: 5ʹ-TGCCCTCTACTTCAACGG-3ʹ, PAI-1-R: 5ʹ-GTCGGTCATTCCCAGGTT-3ʹ; β-actin-F: 5ʹ-ATCTGGCACCACACCTTCTA-3ʹ, β-actin-R: 5ʹ-CTCGGTGAGGTCTCATGA-3ʹ.
ELISA for PAI-1, NF-kB, and PKA ELISA kits were used to detect the expression of PAI-1 (Human PAI-1 Total Antigen Assay; Molecular Innovations, Novi, MI, USA), NF-kB (P65) activity (KAA065; Rockland, Limerick, PA, USA), and PKA activity (K027-H1; Arbor Assays, Ann Arbor, MI, USA), according to the manufacturers' protocols.
Western blotting
HUVECs treated under the various conditions described in the Cell treatments section above were washed twice with ice-cold PBS and resuspended in ice-cold RIPA buffer containing 1 mMphenylmethanesulfonyl fluoride and a cocktail of protease inhibitors (1:100 dilution; Beyotime, Nantong, China). Samples were centrifuged at 4°C for 15 min at 14, 000 rpm. Supernatants were recovered and total proteins were quantified using a BCA Protein Assay kit (Thermo Scientific Pierce, Rockford, IL, USA). The western blot analysis was carried out according to our previous description [13] . Briefly, equal amounts of protein were loaded and separated on 8-12% sodium dodecyl sulfate-polyacrylamide gels and transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). The membranes were blocked for 1 h at room temperature with 5% milk in Tris-buffered saline containing 0.05% Tween-20 (TBST). They were then incubated for 1 h with the primary antibodies (anti-AMPK, 1:2, 000; anti-p-AMPK, 1:2, 000; Abcam, Cambridge, MA, USA), washed three times with TBST, incubated with the secondary antibody for 40 min, washed three more times with TBST, and finally visualized using Immobilon Western Chemiluminescent HRP Substrate (Millipore).
cAMP assays
The cells (2 × 10 5 cells/well) were seeded in wells of a 24-well plate. After experimental treatment, the incubation medium was aspirated. The cells were lysed with 200 μl of 1 M HCl containing 0.1% Triton X-100, and the lysis solution was then transferred to microcentrifuge tubes. After centrifugation at 1300 × g for 5 min at room temperature, the cellular cAMP concentrations in the supernatants were determined using a direct enzyme immunoassay kit (Amersham Biosciences, Little Chalfont, UK) according to the manufacturer's instructions.
Promoter constructs, mutagenesis, and luciferase assay
The upstream promoter fragments located at 1000 bp from the transcriptional start site of the human PAI-1 promoter were generated by PCR amplification from human genomic DNA and inserted into the pGL3 promoter vector carrying the firefly luciferase reporter gene (Promega). The NF-kB-binding sites from -288 bp to -297 bp of the full-length PAI-1 promoter region were identified using ConSite (http:// consite.genereg.net/). Site-directed mutagenesis was then employed to mutate each predicted binding site using QuikChange II Site-Directed Mutagenesis Kits (Agilent Technologies, Santa Clara, CA, USA). All of the PAI-1 promoter constructs generated were confirmed by DNA sequencing. The plasmid DNA constructs were transfected into HUVECs for 24 h and then the cells were disrupted using a lysis buffer (Promega). The resultant cell lysate (20 µl) was mixed with luciferase reagent (50 µl), and the luminescent value was measured. All assays were carried out in triplicate.
ChIP assays
Each group of cells was cross-linked with 1% formaldehyde for 10 min at room temperature and subsequently quenched with glycine. The cells were lysed and the nuclei were isolated from the transfected cells. The resultant chromatin was resuspended in Lysis Buffer 3 (10 mMTris-HCl, pH 8.0, 100 mMNaCl, 1 mMethylenediaminetetraacetic acid [EDTA], 0.5 mM ethylene glycol tetraacetic acid, 0.1% Na-deoxycholate, 0.5% N-lauroylsarcosine, and a cocktail of protease inhibitors) and sonicated to obtain DNA fragments of 100-1000 bp. The samples were treated with 1% Triton X-100 (final concentration) and subjected to centrifugation at 20, 000 × g at 4°C for 10 min. The supernatants of the samples were incubated overnight at 4°C on a rotator with either 4 µg of NF-kB antibody or IgG antibody, which served as the sham control. Following incubation, 25 µl of magnetic A/G beads (Thermo Scientific) was added to each reaction, and the suspension was incubated for 3 h at 4°C with rotation. The beads were washed four times with RIPA buffer (10 mMTris-HCl, 0.25 M LiCl, 0.5% NP-40, and 0.5% sodium deoxycholate, pH 7.5) and two times with Tris-EDTA buffer supplemented with 50 mMNaCl. The cross-linking was disrupted by treatment with 10% Chelex-100 by boiling. The samples were treated with RNase A and Proteinase K. The resultant DNA was used as a template to analyze the NF-kB-binding region within the PAI-1 promoter. The abundance of promoter sequences that were bound by NF-kB was analyzed by real-time PCR using 2 µl of the DNA as a template. The experiments were repeated at least three times in triplicate, and the qRT-PCR results are expressed as the percentage of the input [14] .
Statistical analysis
Statistical analysis was performed using SPSS 19.0 software (IBM, Chicago, IL, USA). The results are shown as means ± standard deviation and analyzed using one-way ANOVA followed by post-hoc LSD test. A value of P < 0.05 was considered statistically significant.
Results
TNF-α upregulates PAI-1 expression
The qRT-PCR and ELISA results showed that the treatment of HUVECs with TNF-α for 5 h could upregulate PAI-1 mRNA expression and PAI-1 antigen levels at all concentrations tested from 1 ng/ml to 100 ng/ml (Fig. 1A, B) , with both levels showing a peak in response to 10 ng/ml TNF-α. We further detected PAI-1 mRNA and antigen levels after 10 ng/ml TNF-α treatment at different time points. Both the mRNA and antigen levels increased dramatically after 1 h of treatment, reached a peak at 6 h, and then were maintained at this high level thereafter (Fig. 1C, D) . Therefore, treatment with 10 ng/ml TNF-α for 6 h was used for subsequent assays.
Adp prevents TNF-α-induced PAI-1 upregulation
To investigate the role of Adp in regulating the TNF-α-induced PAI-1 upregulation, HUVECs were treated with 10 ng/ml TNF-α with or without various concentrations of Adp (10 µg/ml, 20 µg/ml, 30 µg/ml) for 6 h. The qRT-PCR and ELISA results showed that Adp co-treatment could decrease the TNF-α-induced PAI-1 mRNA and antigen levels at all concentrations ( Fig. 2A, B) in a dose-dependent manner. These results indicated that Adp could inhibit TNF-α-activated PAI-1 expression.
Adp inhibits TNF-α-induced PAI-1 by activating the cAMP-PKA-AMPK signaling pathway
To investigate the mechanism by which Adp inhibits TNF-α-activated PAI-1 expression, we evaluated the potential role of the cAMP-PKA-AMPK signaling pathway. As shown in Fig. 3 A-C, TNF-α treatment inactivated the cAMP-PKA-AMPK signaling pathway, and Adp co-treatment weakened this effect. Furthermore, co-treatment with the cAMP inhibitor Fig. 1 . The effect of TNF-α on PAI-1 mRNA and antigen levels in HUVECs. A) PAI-1 mRNA levels after treatment with various concentrations of TNF-α (1 ng/ml, 10 ng/ml, 20 ng/ml, 50 ng/ml, and 100 ng/ml). B) PAI-1 antigen levels after treatment with various concentrations of TNF-α (1 ng/ml, 10 ng/ml, 20 ng/ml, 50 ng/ml, and 100 ng/ml). C) PAI-1 mRNA levels after treatment with 10 ng/ml TNF-α at different time points. D) PAI-1 antigen levels after treatment with 10 ng/ml TNF-α at different time points. * P<0.05. Fig. 2 . The effect of adiponectin (Adp) on TNF-α-induced PAI-1 upregulation in HUVECs. A) PAI-1 mRNA levels after treatment with various concentrations of Adp (10 µg/ml, 20 µg/ml, 30 µg/ml) plus 10 ng/ml TNF-α. B) PAI-1 antigen levels after treatment with various concentrations of Adp (10 µg/ml, 20 µg/ml, 30 µg/ml) plus 10 ng/ml TNF-α. * P<0.05.
Rp-cAMP or activator forskolinincreased or decreased the PAI-1 mRNA and antigen levels, respectively, compared to the levels observed using 30 µg/ml Adp and 10 ng/ml TNF-α alone (Fig. 3D, E) . These results revealed that Adp inhibits TNF-α-induced PAI-1 by activating the cAMP-PKA-AMPK signaling pathway.
Adp inhibits TNF-α-induced PAI-1 by suppressing the binding capacity of NF-κB on the PAI-1 promoter
A binding site of NF-κB was found in the PAI-1 promoter from -288 bp to -297 bp (GGTATTCCCC). Therefore, we investigated the role of NF-κB in regulating PAI-1 transcription. As shown in Fig. 4A , 10 ng/ml TNF-α treatment increased NF-κB activity, which was significantly decreased by treatment with 30 µg/ml Adp plus 10 ng/ml TNF-α. In addition, the ChIP assays showed that TNF-α treatment increased the luciferase activity of the wild-type full-length PAI-1 promoter construct, which was decreased by 30 µg/ml Adp plus 10 ng/ml TNF-α; however, this co-treatment had no obvious effect on the luciferase activity of the mutant-type full-length PAI-1 promoter construct. As shown in Fig. 4C , TNF-α Fig. 3 . Adiponectin (Adp) inhibits TNF-α-induced PAI-1 upregulation by activating the cAMP-PKA-AMPK signaling pathway. A) Effect of 30 µg/ml Adp and/or 10 ng/ml TNF-α treatment on cAMP levels. B) Effect of 30 µg/ml Adp and/or 10 ng/ml TNF-α treatment on PKA activity. C) Representative gel (left) and quantification (right) of the effect of 30 µg/ml Adp and/or 10 ng/ml TNF-α treatment on the AMPK phosphorylation level. D) Effect of co-treatment with the cAMP inhibitor Rp-cAMPs or cAMP activator forskolinplus 30 µg/ ml Adp and 10 ng/ml TNF-α on the PAI-1 mRNA level. E) Effect of co-treatment with the cAMP inhibitor RpcAMPs or the cAMP activator forskolinplus 30 µg/ml Adp and 10 ng/ml TNF-α on the PAI-1 antigen level. Fig. 4 . Adiponectin (Adp) inhibits TNF-α-induced PAI-1 upregulation by suppressing the binding capacity of NF-κB on the PAI-1 promoter. HUVECs were treated with 30 µg/ml Adp and/or 10 ng/ml TNF-α, and cells were harvested for A) NF-κB activity detection, B) luciferase assays, and C) ChIP assays to detect the binding capacity of NF-κB on the PAI-1 promoter. * P < 0. 05 Fig. 5 . Adiponectin (Adp) suppresses NF-κB activity and binding capacity by activating the cAMP-PKA-AMPK signaling pathway. HUVECs were treated with the cAMP inhibitor Rp-cAMPs or activator forskolinplus 30 µg/ml Adp and 10 ng/ml TNF-α cells were harvested for A) NF-κB activity detection, B) luciferase assays, and C) ChIP assays to detect the binding capacity of NF-κB on the PAI-1 promoter. *P<0.05. cAMPs or forskolin co-treatment, respectively, increased or decreased NF-κB binding on the PAI-1 promoter compared to that of the 30 µg/ml Adp and 10 ng/ml TNF-α treatment. These results further indicated that Adp suppresses NF-kB activity and binding by activating the cAMP-PKA-AMPK signaling pathway.
Discussion
The abnormal function of the fibrinolytic system is acausal pathophysiological factor in atherosclerosis [4, 15] . Several studies have shown that PAI-1 deficiency is associated with a reduced tissue fibrosis. PAI-1 is a plausible target for controlling the pathogenesis of fibrosis [5] ; accordingly, it is critical to find new methods to decrease PAI-1 expression for the treatment and prevention of fibrosis-related diseases, such as atherosclerosis-associated cardiovascular disease. As one of the key regulatory factors in the fibrinolysis process of plasmin, TGF-α positively regulates PAI-1 expression in many cell types, such as granulosa cells, the human hepatoma cell line HepG2, and HUVECs [8, 16, 17] . Therefore, we aimed to identify regulators of TGF-α-induced PAI-1 upregulation. We demonstrated that Adp could decrease the TNF-α-induced elevation of PAI-1, a major regulator of the fibrinolytic system. In addition, we found that Adp exerts these regulatory effects via thecAMP-PKA-AMPK-NF-κB axis. Our results provide new insight into the molecular mechanisms underlying the development of atherosclerosis-associated cardiovascular disease and suggest therapeutic strategies.
Adp appears to regulate plaque inflammation and stability by functioning as an antiinflammatory adipocytokine that reduces the production of inflammatory cytokines and chemokines, such as TNF-α [18, 19] . In addition, TNF-α upregulates PAI-1 expression in pleural mesothelial cells [20] . However, this is the first study to show that Adp plays a role in TNF-a-induced PAI-1 expression at both the mRNA and protein levels in a dose-dependent manner in HUVECs. Collectively, these results reveal that Adp might play an important role in regulating the fibrinolytic system. In addition, elevated PAI-1 levels may be involved in obesity, metabolic syndrome, diabetes mellitus, thrombosis, endometriosis, atherosclerosis, cancer, and multiple organ fibrosis [21] [22] [23] [24] ; we predicated that Adp may be utilized as a novel agent in the treatment of these human diseases. However, to assess the effects of Adp on fibrinolytic balance, theexpressionlevels of t-PA, u-PA, and u-PA receptor (u-PAR) need to be examined because fibrinolysis is determined by a balance of inhibitors and activators.
PAI is clearly induced by TNF-α. However, the exact mechanisms of PAI-1 expression are complex and remain to be elucidated. Various transcription factors, such as CREBbinding protein, upstream stimulatory factors 1 and 2, Smad2, Smad3, CCAAT box-binding transcription factor, specificity protein 1, and p53, have been implicated in the regulation of PAI-1 expression [25] . However, the regulatory mechanism of PAI-1 expression is cell typedependent [26] . TNF-α elicits an inflammatory response via several signal transduction pathways, including the NF-kB pathway [27] . Given that the PAI-I promoter contains a binding site for NF-kB, we hypothesized that Adp regulates TNF-α-induced PAI-1 expression by altering the binding ability of NF-kB. This hypothesis was supported by the results of luciferase and ChIP assays, clearly showing that Adp inhibits TNF-α-induced increases in NF-κB binding to the PAI-1 promoter, but not to a mutated promoter construct. Therefore, Adp appears to regulate TNF-α-induced PAI-1 antigen expression by transcriptional regulation by affecting the binding activity of NF-kB. However, other transcription factor-binding sites have also been identified on the PAI-1 promoter, such as binding sites for AP-1 and SP-1 [20, 28] . For example, glutathione suppresses transforming growth factor-beta-induced PAI-1 expression by inhibiting the binding of AP-1 or SP-1 to the PAI-1 promoter [28] . Therefore, further studies are needed to identify the relationships between these transcription factors with respect to the inhibitory mechanism of Adp on TNF-α-induced PAI-1 mRNA upregulation.
Extensive evidence indicates that canonical and non-canonical pathways, such as epidermal growth factor receptor, Src kinase, and mitogen-activated protein kinase
